Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027960 (mole)
 21,279 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Monoclonal antibody PAL-M1, which was selected to discriminate between nevocellular nevi and cutaneous melanomas, has not been characterized until now. Here we show that PAL-M1 is directed against the transferrin receptor (CD71). The molecules precipitated by PAL-M1 and by anti-transferrin receptor antibodies OKT9 and 5E9 from various human tumor cell lines (melanoma, hepatoma, and lymphoma) show identical characteristics on SDS-PAGE. PAL-M1 also specifically recognized mouse L cells expressing the human transferrin receptor gene. Competition experiments demonstrated that PAL-M1 and OKT9 recognize the same or a spatially close determinant. Immunohistochemical staining of a large series of melanocytic lesions indicates that the transferrin receptor can be considered as a progression antigen in this type of lesion.
 ...
PMID:Monoclonal antibody PAL-M1 recognizes the transferrin receptor and is a progression marker in melanocytic lesions. 236 2

Monoclonal antibodies (MoAbs) against six well-defined progression-associated melanoma antigens (PAMAs) and a MoAb against the nuclear proliferation-associated antigen Ki67 were used for an immunoperoxidase study on 44 biopsies from 36 congenital melanocytic nevi (CMN). Twenty-nine common acquired nevi and 16 metastasizing primary melanomas were studied as controls. Two CMN of the series were giant CMN (greater than 20 cm), one of which later progressed to metastasizing melanoma. Of the remaining 34 CMN, four were histologically associated with a malignant melanoma. DNA flow cytometry was performed on adjacent cryostat sections of 37 biopsies from 28 CMN without melanoma. PAMAs were found expressed in CMN in the following frequencies: A-1-43: 36%; P358: 27%; PAL-M1: 20%; HLA-DR: 9%; Muc 18: 2%; A-10-33: 0%. No PAMAs were present in only 15 biopsies (34%). One single PAMA was found in 20 lesions (45%), and two or more PAMAs in nine lesions (21%). In all four CMN histologically associated with melanoma, and also in one biopsy from the giant CMN which later progressed to melanoma, at least two PAMAs were expressed. The latter biopsy was the only CMN in which the proliferation-associated antigen could be demonstrated. Only this biopsy and a single biopsy of the other giant CMN showed aneuploidy. We found expression of single PAMAs and co-expression of PAMAs in CMN in higher frequency than in common acquired melanocytic nevi. Co-expression of PAMAs was a feature of metastasizing primary melanomas. We conclude that co-expression of two or more PAMAs in a CMN might indicate its malignant potential, because this was found in all CMN proven to have progressed to malignant melanoma.
 ...
PMID:Immunohistologic evidence for the malignant potential of congenital melanocytic nevi. 264 72

Fatty acid-binding protein (FABP) was isolated, purified, and characterized from developing human fetal lung cytosol by gel filtration and ion-exchange chromatography. FABP exists in three immunochemically identical forms, DE-I, DE-II, and DE-III, having Mr 15,200 +/- 200 each and isoelectric pH 7.8, 6.9, and 5.4, respectively. DE-I is almost lipid-free, DE-II binds mainly long-chain unsaturated fatty acids, and DE-III is an arachidonic acid carrier. One mole of DE-II and DE-III each binds 1 mol of fatty acids noncovalently. Concentrations of all these FABPs increase gradually from early gestation to term. Defatted lung FABP reverses the inhibitory effect of palmitoyl coenzyme A (CoA) (PAL-CoA) on lung glucose-6-phosphate dehydrogenase (G6PD), a key enzyme of the hexose monophosphate (HMP) shunt pathway. This protein when added alone activates the enzyme, suggesting that the original submaximal activity is probably due to the presence of endogenous long-chain fatty acyl CoA esters in the cytosols. As FABP is present in relatively high concentration in most mammalian cells, the potent inhibitory effects of long-chain acyl CoA esters on the HMP shunt pathway in vitro are not seen in intact cells.
 ...
PMID:Purification and characterization of fatty acid-binding proteins from human fetal lung. 276 6

We describe a 13-year-old girl with multiple pigmented nodules and plaques arranged in a cluster in the right lumbar region, which had developed since infancy. Eleven of 15 lesions which were examined histologically were found to be Spitz naevi. The remaining four lesions were compound naevocellular naevi, and two of them showed focal dysplasia. Eight Spitz naevi were investigated immunohistologically with monoclonal antibodies against HLA-antigens and malignancy-associated melanocytic antigens which are rarely present in common naevi. Naevus cells in all lesions expressed HLA-ABC antigens, but lacked HLA-DR antigens in seven of the eight lesions. All naevi were positive for 'constitutive' (KG-6-56) and 'early' (K-1-2) markers of naevomelanocytic cells. In five of the eight Spitz naevi, at least one of the three malignancy-associated melanocytic antigens PAL-M1, A-1-43 and A-10-33 was found. The expression of malignancy-associated antigens in multiple agminate Spitz naevi is at variance with their benign clinical course.
 ...
PMID:Multiple agminate Spitz naevi: review of the literature and report of a case with distinctive immunohistological features. 331 74

Two monoclonal antibodies (MoAbs), PAL-M1 and PAL-M2, are described that were selected to discriminate between melanomas and nevocellular nevi (NN) in frozen sections. MoAb PAL-M1 reacted with all 15 melanoma metastases (MM), with 14 of 19 primary cutaneous melanomas (PCM), 9 of 35 dysplastic nevi (DN), and 2 of 26 NN. The 2 NN stained were removed from patients with the dysplastic nevus syndrome. MoAb PAL-M2 reacted with 9 of 15 MM, 5 of 19 PCM, 3 of 35 DN, and did not react with 26 NN after usual staining conditions. The proportion of melanocytic cells stained was low in DN and much higher in PCM and especially in MM. Staining in DN was restricted to intraepidermal or subepidermal nests of atypical melanocytes. In PCM, staining with PAL-M2 was observed only in tumors with a Breslow thickness of 0.76 mm or higher. PAL-M1 and PAL-M2 may be immunohistochemical markers for tumor progression in melanocytic proliferations.
 ...
PMID:Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi. 389 75